Thymosin β4 Alleviates Autoimmune Dacryoadenitis via Suppressing Th17 Cell Response.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Thymosin β4 Alleviates Autoimmune Dacryoadenitis via Suppressing Th17 Cell Response.
- Published In:
- Investigative ophthalmology & visual science, 64(11), 3 (2023)
- Authors:
- Zhao, Xiaoyu, Li, Na(7), Yang, Ning, Mi, Baoyue, Dang, Weiyu, Sun, Deming, Ma, Shanshan, Nian, Hong, Wei, Ruihua
- Database ID:
- RPEP-07636
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07636APA
Zhao, Xiaoyu; Li, Na; Yang, Ning; Mi, Baoyue; Dang, Weiyu; Sun, Deming; Ma, Shanshan; Nian, Hong; Wei, Ruihua. (2023). Thymosin β4 Alleviates Autoimmune Dacryoadenitis via Suppressing Th17 Cell Response.. Investigative ophthalmology & visual science, 64(11), 3. https://doi.org/10.1167/iovs.64.11.3
MLA
Zhao, Xiaoyu, et al. "Thymosin β4 Alleviates Autoimmune Dacryoadenitis via Suppressing Th17 Cell Response.." Investigative ophthalmology & visual science, 2023. https://doi.org/10.1167/iovs.64.11.3
RethinkPeptides
RethinkPeptides Research Database. "Thymosin β4 Alleviates Autoimmune Dacryoadenitis via Suppres..." RPEP-07636. Retrieved from https://rethinkpeptides.com/research/zhao-2023-thymosin-4-alleviates-autoimmune
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.